Table 1.
Baseline characteristics
| rs622342 | AA | AC | CC | |
|---|---|---|---|---|
| N | 39 | 49 | 11 | |
| Gender, male (%) | 17 (43%) | 22 (45%) | 3 (27%) | |
| Age, year (SD) | 77.7 (7.1) | 78.0 (7.4) | 78.8 (7.5) | |
| Follow-up, year (SD) | In Rotterdam Study | 11.8 (4.5) | 10.0 (4.1) | 9.4 (5.0) |
| After start levodopa | 5.0 (3.8) | 4.6 (3.6) | 3.5 (2.6) | |
| Body-mass index, kg/m2 (SD) a | 28.2 (6.3) | 26.2 (3.9) | 27.6 (4.8) | |
| Creatinine level, μmol/l (SD) a | 85.9 (16.5) | 79.9 (14.2) | 79.8 (9.7) | |
| Prior use before start levodopa therapy | Anticholinergic drugs | 5 (13%) | 7 (14%) | 1 (9%) |
| Dopamine agonists | 3 (8%) | 4 (8%) | 1 (9%) | |
| Amantadine | 12 (31%) | 11 (22%) | 5 (45%) | |
| Selegiline | 13 (33%) | 15 (31%) | 4 (36%) | |
| Average prescribed dose of non-levodopa anti-Parkinsonian drugs at start levodopa therapy | 0.84 DDD | 0.80 DDD | 0.68 DDD | |
aAt the time of entrance in the Rotterdam Study